Mesoblast logo

MSB - Mesoblast Share Price

A$1.74 -0.0  -2.5%

Last Trade - 7:10am

Mid Cap
Market Cap £572.2m
Enterprise Value £588.4m
Revenue £11.8m
Position in Universe 290th / 1907
Unlock MSB Revenue
Relative Strength (%)
1m -22.9%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -69.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
19.8 42.5 2.41 17.3 16.7 32.2 67.2 113 +10.2%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 31 December 2020, Mesoblastlimited revenues decreased 82% to $3.5M. Net loss increased67% to $50.2M. Revenues reflect Milestone revenue decreasefrom $15M to $0K, Interest revenue decrease of 95% to $21K,Commercialization revenue decrease of 9% to $3.5M. Highernet loss reflects Stock-based Compensation in R&D increasefrom $970K to $5.1M (expense), Research and development -Balancing val increase of 11% to $27.7M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for MSB
Graphical History


MSB Revenue Unlock MSB Revenue

Net Income

MSB Net Income Unlock MSB Revenue

Normalised EPS

MSB Normalised EPS Unlock MSB Revenue

PE Ratio Range

MSB PE Ratio Range Unlock MSB Revenue

Dividend Yield Range

MSB Dividend Yield Range Unlock MSB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
MSB EPS Forecasts Unlock MSB Revenue
Profile Summary

Mesoblast Limited is engaged in the development of regenerative medicine products. The Company’s regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high and unmet medical needs. The Company’s portfolio of Phase III product candidates comprises RYONCIL (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD), REVASCOR for advanced chronic heart failure (CHF) and MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company's product candidate, MPC-150-IM, is in Phase III trials for the treatment of both advanced and end-stage CHF. The Company has conducted Phase II trial of MPC-300-IV in patients with biologic-refractory rheumatoid arthritis. The Company is developing MPC-25-Osteo for spinal fusion.

Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated June 8, 2004
Public Since December 16, 2004
No. of Shareholders: 37,476
No. of Employees: 102
Sector Healthcare
Industry Biotechnology & Medical Research
Index S&P/ASX All Ordinaries , S&P/ASX 200 , S&P/ASX 300 , ASX Small Ordinaries ,
Exchange Australian Stock Exchange - SEATS
Shares in Issue 587,003,466
Free Float (0.0%)
Eligible for
MSB Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for MSB
Upcoming Events for MSB
Wednesday 26th May, 2021 Estimate
Q3 2021 Mesoblast Ltd Earnings Release
Wednesday 25th August, 2021 Estimate
Full Year 2021 Mesoblast Ltd Earnings Release
Frequently Asked Questions for Mesoblast
What is the Mesoblast share price?

As of 7:10am, shares in Mesoblast are trading at A$1.74, giving the company a market capitalisation of £572.2m. This share price information is delayed by 15 minutes.

How has the Mesoblast share price performed this year?

Shares in Mesoblast are currently trading at A$1.74 and the price has moved by -50.85% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Mesoblast price has moved by -63.43% over the past year.

What are the analyst and broker recommendations for Mesoblast?

Of the analysts with advisory recommendations for Mesoblast, there are there are currently 0 "buy" , 2 "hold" and 1 "sell" recommendations. The overall consensus recommendation for Mesoblast is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Mesoblast next release its financial results?

Mesoblast is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Mesoblast dividend yield?

Mesoblast does not currently pay a dividend.

Does Mesoblast pay a dividend?

Mesoblast does not currently pay a dividend.

When does Mesoblast next pay dividends?

Mesoblast does not currently pay a dividend.

How do I buy Mesoblast shares?

To buy shares in Mesoblast you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Mesoblast?

Shares in Mesoblast are currently trading at A$1.74, giving the company a market capitalisation of £572.2m.

Where are Mesoblast shares listed? Where are Mesoblast shares listed?

Here are the trading details for Mesoblast:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: MSB
What kind of share is Mesoblast?

Based on an overall assessment of its quality, value and momentum, Mesoblast is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Mesoblast share price forecast 2021?

Shares in Mesoblast are currently priced at A$1.74. At that level they are trading at 0.16% discount to the analyst consensus target price of 0.00.

Analysts covering Mesoblast currently have a consensus Earnings Per Share (EPS) forecast of -0.085 for the next financial year.

How can I tell whether the Mesoblast share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mesoblast. Over the past six months, the relative strength of its shares against the market has been -51.63%. At the current price of A$1.74, shares in Mesoblast are trading at -46.66% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Mesoblast PE Ratio?

We were not able to find PE ratio data for Mesoblast.

Who are the key directors of Mesoblast?

Mesoblast's management team is headed by:

Michael Spooner - NID
Silviu Itescu - CEO
Donal O'Dwyer - NID
Eric Rose - NID
William Burns - VCH
Peter Howard - GCN
Paul Simmons - OTH
John McMannis - OTH
Geraldine Storton - OTH
Joshua Muntner - CFO
Joseph Swedish - NEC
Eric Strati - SVP
Fred Grossman - OTH
Dagmar Rosa-Bjorkeson - COO
Philip Facchina - DRC
Who are the major shareholders of Mesoblast?

Here are the top five shareholders of Mesoblast based on the size of their shareholding:

Itescu (Silviu) Individual Investor
Percentage owned: 10.63% (69.0m shares)
M & G Investment Management Ltd. Investment Advisor
Percentage owned: 7.98% (51.8m shares)
M&G Recovery Fund Mutual Fund
Percentage owned: 6.76% (43.8m shares)
TIGA Trading Pty Ltd Investment Advisor
Percentage owned: 4.7% (30.5m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 1.85% (12.0m shares)
Similar to MSB
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.